Pharmaceutical compositions and related methods of delivery

Abstract

The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.

1 - 195 . (canceled) 
     
     
         196 . A method of prophylactically treating a subject for variceal bleeding, which comprises orally administering to the subject a somatostatin analog or a composition comprising a somatostatin analog. 
     
     
         197 . The method of  claim 196 , wherein the somatostatin analog is octeotride. 
     
     
         198 . The method of  claim 196 , wherein the prophylaxis is primary. 
     
     
         199 . The method of  claim 196 , wherein the prophylaxis is secondary. 
     
     
         200 . The method of  claim 196 , wherein the variceal bleeding is associated with portal hypertension. 
     
     
         201 . The method of  claim 196 , wherein the varices are gastric or esophageal. 
     
     
         202 . The method of  claim 196 , wherein the somatostatin analog is administered once daily. 
     
     
         203 . The method of  claim 196 , wherein the somatostatin analog is administered twice or more daily. 
     
     
         204 . A method of treating a subject suffering from portal hypertension or variceal bleeding, comprising orally administering to the subject a somatostatin analog or a composition comprising a somatostatin analog. 
     
     
         205 . The method of  claim 204 , wherein the somatostatin analog is octeotride. 
     
     
         206 . The method of  claim 204 , wherein the subject suffers from variceal bleeding. 
     
     
         207 . The method of  claim 204 , wherein the varices are gastric or esophageal. 
     
     
         208 . The method of  claim 204 , wherein the subject suffers from portal hypertension. 
     
     
         209 . The method of  claim 204 , wherein the therapeutic agent is administered once daily. 
     
     
         210 . The method of  claim 204 , wherein the therapeutic agent is administered twice or more daily. 
     
     
         211 . A method of treating a subject suffering from abnormal GI motility, flushing episodes associated with carcinoid syndrome, an endocrine tumor (such as carcinoids, VIPoma), gastroparesis, diarrhea, pancreatic leak or a pancreatic pseudo-cyst, or hepato-renal syndrome, shock of hypovolemic (e.g. hemorrhagic) or vasodilatory (e.g. septic) origin, cardiopulmonary resuscitation or anesthesia-induced hypotension, comprising orally administering to the subject a somatostatin analog or a composition comprising a somatostatin analog. 
     
     
         212 . The method of  claim 211 , wherein the somatostatin analog is octeotride. 
     
     
         213 . A method of prophylactically treating a subject for variceal bleeding, which comprises orally administering to the subject a vasopressin analog or a composition comprising a vasopressin analog. 
     
     
         214 . The method of  claim 213 , wherein the vasopressin analog is terlipressin. 
     
     
         215 . The method of  claim 213 , wherein the prophylaxis is primary. 
     
     
         216 . The method of  claim 213 , wherein the prophylaxis is secondary. 
     
     
         217 . The method of  claim 213 , wherein the variceal bleeding is associated with portal hypertension. 
     
     
         218 . The method of  claim 213 , wherein the therapeutic agent is administered once daily. 
     
     
         219 . The method of  claim 213 , wherein the therapeutic agent is administered twice or more daily. 
     
     
         220 . A method of treating a subject suffering from hepato-renal syndrome (HRS), bleeding esophageal varices or portal hypertension, which comprises orally administering to the subject a vasopressin analog or a composition comprising a vasopressin analog. 
     
     
         221 . The method of  claim 220 , wherein the subject suffers from hepato-renal syndrome (HRS). 
     
     
         222 . The method of  claim 220 , wherein the hepato-renal syndrome (HRS) is HRS I. 
     
     
         223 . The method of  claim 220 , wherein the hepato-renal syndrome (HRS) is HRS II. 
     
     
         224 . The method of  claim 220 , wherein the subject suffers from bleeding esophageal varices. 
     
     
         225 . The method of  claim 220 , wherein the subject suffers from portal hypertension. 
     
     
         226 . The method of  claim 220 , wherein the vasopres sin analog is terlipressin. 
     
     
         227 . The method of  claim 220 , wherein the variceal bleeding is associated with portal hypertension. 
     
     
         228 . The method of  claim 220 , wherein the varices are gastric or esophageal. 
     
     
         229 . The method of  claim 220 , wherein the therapeutic agent is administered once daily. 
     
     
         230 . The method of  claim 220 , wherein the therapeutic agent is administered twice or more daily.